About BioXell
BioXell is a company based in Segrate (Italy) founded in 2002 was acquired by Cosmo Pharmaceuticals in November 2009. BioXell has raised $79.28 million across 5 funding rounds from investors including Cosmo Pharmaceuticals, Life Sciences Partners and BB Biotech. BioXell operates in a competitive market with competitors including Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Segrate, Italy
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website bioxell.com
- Acquired by Cosmo Pharmaceuticals (Nov 2009)
- Total Equity Funding$79.28M (USD)
in 5 rounds
- Latest Funding Round$12.57M (USD), Series C
Mar 2006
- InvestorsCosmo Pharmaceuticals
& 8 more
- Acquired byCosmo Pharmaceuticals
(Nov 2009)
Funding Insights of BioXell
BioXell has successfully raised a total of $79.28M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $12.57 million completed in March 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $79.28M
- Total Rounds 5
- Last Round Series C — $12.57M
- First Round $19.3M
(Mar 2002)
- Investors Count 8
All 5 funding rounds of BioXell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2006 | $12.57M | Series C | – | – | |
| Oct 2005 | $8.73M | Grant | – | – | |
| Oct 2005 | $27.51M | Series C | – | – | |
| May 2003 | $19.9M | Series B | – | – | |
| Mar 2002 | $19.3M | Series A | – | – |
9 investors in total: 9 institutional.
Investors in BioXell
BioXell has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Cosmo Pharmaceuticals, Life Sciences Partners and BB Biotech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Venture capital investments in technology startups and entrepreneurs. | – | indexventures.com | - | |
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Capital is invested in life science innovations for healthcare transformation. | – | tvm-capital.com | Munich, Germany | |
Private equity investment firm focused on buyouts | – | alpinvest.com | Amsterdam, Netherlands | |
Invests in biotech firms developing life-saving drugs and technologies. | – | mpmcapital.com | - | |
- | – | qventures.de | - | |
Government body responsible for education and merit in Italy. | – | istruzione.it | Italy | |
Therapeutics for gastrointestinal diseases are developed and provided. | 1996 | cosmopharma.com | Dublin, Ireland |
Investor details for BioXell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioXell
5 dated milestones of BioXell across 7 years, from founding to its latest funding, stage changes and deals.
- Founded BioXell is founded.
- Funding First funding round of $19.3M.
- Funding Latest funding round, Series C, of $12.6M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Cosmo Pharmaceuticals.
Competitors of BioXell
BioXell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Escient Pharmaceuticals, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| alpineimmunesciences.com | 2015 | Seattle, United States | $49.25M | 126 | Developer of immunotherapies to treat cancer and autoimmune disorders | |
| septerna.com | 2020 | San Bruno, United States | $250M | – | GPCR drug discovery platform is developed for multiple diseases. | |
| upstreambio.com | 2021 | Waltham, United States | $400M | – | Therapeutics for allergic and inflammatory diseases are developed. | |
| acelyrin.com | 2020 | Los Angeles, United States | $550M | – | Immunological drug candidates are developed for severe diseases. | |
| gossamerbio.com | 2017 | San Diego, United States | $330M | 102 | Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer | |
| calcimedica.com | 2006 | San Diego, United States | $76.66M | 11 | CRAC channel inhibitors are developed for inflammatory diseases. |
Detailed competitors of BioXell
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioxell
Complete news archive for BioXell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to BioXell
10 companies that operate in the same segment as BioXell (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioXell
BioXell was founded in 2002.
BioXell is headquartered in Segrate, Italy. It is registered at Segrate, Lombardy, Italy.
BioXell is a funded company, having raised a total of $79.28M across 5 funding rounds to date. The company's 1st funding round was a Series A of $19.3M, raised on Mar 2002.
BioXell was an Italian, clinical stage biopharma developing small molecule and antibody therapeutics for chronic inflammatory and autoimmune diseases. The company was founded with 22M funding as a spinout of Roche Milano Ricerche, a leading biomedical research institute. BioXell worked on urology, inflammation, pain, and other related disorders. The company was focusing on the development of monoclonal antibody BXL1H5 for the treatment of chronic pain- This was later licensed to Novo Nordisk. Its lead compound, Elocalcitol, a VD3 analog, has completed a Phase IIb clinical trial in benign prostatic hyperplasia and a Phase IIb clinical trial in overactive bladder. The company is also developing BXL746, a vitamin D analog under Phase I clinical trail, for the prevention of post-surgical adhesion formation. BioXell had a license and collaboration agreement with Merck for the development of therapeutic and diagnostic products related to triggering receptors expressed on myeloid cells. The company was acquired by Cosmo Pharma in Nov 2009 for 41M.
BioXell's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
BioXell has 9 investors. Key investors include Cosmo Pharmaceuticals, Life Sciences Partners, BB Biotech, Index Ventures, and TVM Capital Life Science.
Yes. BioXell was acquired by Cosmo Pharmaceuticals in November 2009.